Sec Form 4 Filing - Pieper Steven @ XERIS PHARMACEUTICALS INC - 2021-10-05

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Pieper Steven 2. Issuer Name and Ticker or Trading Symbol XERIS PHARMACEUTICALS INC [ XERS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600 3. Date of Earliest Transaction (MM/DD/YY) 10/05/2021 (Street) CHICAGO, IL60601 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/05/2021 D( 1 )( 2 ) 23,775 D 134,333 D Common Stock ( 3 ) 10/05/2021 D( 3 ) 134,333 D 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 1.5 5 10/05/2021 D( 4 ) 16,843 ( 5 ) 02/04/2027 Common Stock 16,843 ( 4 ) 0 D Stock Option (Right to Buy) $ 1.55 10/05/2021 D( 4 ) 2,640 ( 5 ) 06/12/2027 Common Stock 2,640 ( 4 ) 0 D Stock Option (Right to Buy) $ 5.93 10/05/2021 D( 4 ) 14,036 ( 6 )( 8 ) 01/31/2028 Common Stock 14,036 ( 4 ) 0 D Stock Option (Right to Buy) $ 6.37 10/05/2021 D( 4 ) 12,500 ( 6 ) 01/31/2030 Common Stock 12,500 ( 4 ) 0 D Stock Option (Right to Buy) $ 4.09 10/05/2021 D( 4 ) 27,891 ( 7 ) 12/10/2030 Common Stock 27,891 ( 4 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Pieper Steven C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1600 CHICAGO, IL60601 Chief Financial Officer Signatures /s/ Beth Hecht, as Attorney-in-Fact 10/05/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). ( 2 )(Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax. ( 3 )Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the "Xeris RSU"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the "HoldCo RSU") on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time. ( 4 )At the Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. ( 5 )These options are fully vested as of the date hereof. ( 6 )25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. ( 7 )50% of these options shall vest on the first anniversary of the vesting commencement date, with the remaining 50% vesting on the second anniversary of the commencement date. ( 8 )These options are early exercisable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.